Key result
Dabigatran 150 mg significantly prolonged aPTT at 4 and 8 hours compared to 110 mg, and total aPTT increase strongly correlated with baseline values (r=0.96 for 150 mg, r=0.83 for 110 mg).
Why the study?
Can aPTT be reliably used to assess the anticoagulant effect of dabigatran in patients with non-valvular atrial fibrillation?
Observational (n=32)
Can aPTT be reliably used to assess the anticoagulant effect of dabigatran in patients with non-valvular atrial fibrillation?
Effect estimate: r 0.96
aPTT is a useful and reliable screening test for rapidly assessing the anticoagulant effect of dabigatran, which may be valuable in emergency clinical situations.
No takes yet. Share an insight, caveat, or question.
aPTT may aid emergency dabigatran assessment; leaves open reliability for non-valvular AF monitoring.
Antić et al. (2018) conducted an observational in non-valvular atrial fibrillation (n=32). Dabigatran vs. Dabigatran 110 mg twice a day was evaluated on aPTT prolongation (r 0.96). Dabigatran 150 mg significantly prolonged aPTT at 4 and 8 hours compared to 110 mg, and total aPTT increase strongly correlated with baseline values (r=0.96 for 150 mg, r=0.83 for 110 mg).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: